HR-MAS NMR Metabolomics Profile of Vero Cells under the Influence of Virus Infection and nsP2 Inhibitor : A Chikungunya Case Study

The arbovirus Chikungunya (CHIKV) is transmitted by Aedes mosquitoes in urban environments, and in humans, it triggers debilitating symptoms involving long-term complications, including arthritis and Guillain-Barré syndrome. The development of antiviral therapies is relevant, as no efficacious vaccine or drug has yet been approved for clinical application. As a detailed map of molecules underlying the viral infection can be obtained from the metabolome, we validated the metabolic signatures of Vero E6 cells prior to infection (CC), following CHIKV infection (CV) and also upon the inclusion of the nsP2 protease inhibitor wedelolactone (CWV), a coumestan which inhibits viral replication processes. The metabolome groups evidenced significant changes in the levels of lactate, myo-inositol, phosphocholine, glucose, betaine and a few specific amino acids. This study forms a preliminary basis for identifying metabolites through HR-MAS NMR (High Resolution Magic Angle Spinning Nuclear Magnetic Ressonance Spectroscopy) and proposing the affected metabolic pathways of cells following viral infection and upon incorporation of putative antiviral molecules.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:25

Enthalten in:

International journal of molecular sciences - 25(2024), 3 vom: 24. Jan.

Sprache:

Englisch

Beteiligte Personen:

Peinado, Rafaela Dos S [VerfasserIn]
Martins, Lucas G [VerfasserIn]
Pacca, Carolina C [VerfasserIn]
Saivish, Marielena V [VerfasserIn]
Borsatto, Kelly C [VerfasserIn]
Nogueira, Maurício L [VerfasserIn]
Tasic, Ljubica [VerfasserIn]
Arni, Raghuvir K [VerfasserIn]
Eberle, Raphael J [VerfasserIn]
Coronado, Mônika A [VerfasserIn]

Links:

Volltext

Themen:

1H-NMR
Antiviral Agents
Arbovirus
Chikungunya
Journal Article
Metabolomics
Vero cells
Wedelolactone

Anmerkungen:

Date Completed 14.02.2024

Date Revised 02.04.2024

published: Electronic

Citation Status MEDLINE

doi:

10.3390/ijms25031414

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM368281825